根据标普全球市场情报公司提供的数据， Cronos Group 的股价今年已上涨逾一倍。今年第一个月，以大麻为重点的公司中，至少有15家的股价上涨了50%，多国大麻合法化或成主要推动因素。
Shares of Cronos Group have already more than doubled this year, according to data provided by S&P Global Market Intelligence. The Canadian cannabis producer is benefitting from a host of powerful growth catalysts.
根据标普全球市场情报公司提供的数据， Cronos Group 的股价今年已上涨逾一倍。加拿大大麻生产商受益于一系列强大的增长催化剂。
January was an incredible month for pot stocks. No less than 15 marijuana-focused companies saw their stock prices surge by at least 50% in the first month of the year. In stark contrast to 2018, which saw many cannabis stocks plunge in value, investors appear to be taking a more optimistic view of the marijuana industry in 2019.
一月是一个令人难以置信的月份.今年第一个月，以大麻为重点的公司中，至少有15家的股价上涨了50%。与许多大麻股票价值暴跌的2018年形成鲜明对比的是，投资者似乎更看好2019年的大麻产业。
There are many valid reasons to be bullish. Canada legalized recreational marijuana in October. Citizens in several more U.S. states voted to legalize cannabis for medical and recreational purposes in November. And President Trump signed the Farm Bill into law in December, which legalizes the production and sale of hemp and cannabidiol (CBD) derived from the hemp plant. All of these developments should help boost demand for cannabis-based products going forward.
看涨的理由有很多.加拿大10月份将娱乐用大麻合法化。11月，美国其他几个州的公民投票决定将大麻合法化，用于医疗和娱乐目的。去年12月，特朗普总统签署了农业法案，将大麻生产和销售合法化。所有这些发展应有助于推动对以大麻为基础的产品的需求。
Cronos Group also benefited from some stock-specific news. The company struck a blockbuster deal with tobacco titan Altria (NYSE: MO) in December. Altria plans to invest $1.8 billion in Cronos in exchange for a 45% stake. The deal also gives Altria the opportunity to acquire another 10% of Cronos' stock in the future.
Cronos 集团也受益于一些特定股票的新闻。去年12月，该公司与烟草巨头奥驰亚（ NYSE ： MO ）达成了一项重大交易。奥驰亚计划以18亿美元投资克罗诺斯，换取45%的股份。 这笔交易还使奥驰亚有机会在未来获得另外10%的克罗诺斯股票。
Altria brings to the table its vast distribution system and regulatory expertise. And the cash it's injecting in Cronos will allow it to scale up its production and accelerate its international expansion plans.
奥驰亚带来了其庞大的分销系统和监管专业知识。它向克罗诺斯公司注入的资金将使它能够扩大生产并加快其国际扩张计划。
Moreover, Altria's first investment in Cronos may not be its last. It's possible that if the partnership goes well, Altria could acquire Cronos Group's remaining shares -- likely at a sizable premium to where they trade today.
此外，奥驰亚对克罗诺斯的第一笔投资可能不是最后一笔。如果合作关系进展顺利，奥驰亚有可能收购 Cronos Group 的剩余股份，这可能与他们今天的交易相比有相当大的溢价。
閱讀更多 匯眾醫療 的文章
